News and Trends 4 May 2017 French Gene Therapy Biotech Raises a Huge €37.5M in Series A Vivet Therapeutics has raised a huge €37.5M in Series A to help bring a new gene therapy technology for rare liver diseases to the clinic. Vivet Therapeutics has managed to attract some of the hottest biotech investors in Europe in its Series A. Led by Novartis Venture Fund and Columbus Venture Partners, and also counting […] May 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 May 2017 Parent Bacteria Resist Antibiotics Better than their Offspring According to a new study, a phenomenon known as biased inheritance protects older bacteria from the wrath of antibiotics in low concentrations. Older bacteria in a mixed population of dividing E. coli cells inherit a larger number of drug-expelling membrane proteins and pump out antibiotics better than their younger counterparts in the presence of low […] May 4, 2017 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2017 Immuno-oncology Pioneer Enters the Clinic with its RNA-based Therapy Rigontec has announced the start if its first-in-human Phase I/II study with its pioneering RNA-based candidate, RGT100, in solid tumors and lymphoma. Rigontec, based in Munich, is exploring RNA’s applications in immuno-oncology. Since the company was founded in 2014, it has raked in an impressive €30M in series A funding. Now, only 3 years later, the biotech is […] May 3, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2017 E-GUIDE: This is how you bring a molecule to the clinic May 3, 2017 - 0 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2017 New Immuno-oncology Biotech Gets a €20M Series A Funding Boost Imcheck Therapeutics from Marseille has just completed a €20M Series A funding round, backed by big investors like the Boehringer Ingelheim Venture Fund (BIVF). The French biotech Imcheck Therapeutics was founded in 2015 as a spin-off from the Paoli-Calmettes Cancer Institute (IPC) in Marseille and is developing next-generation immunomodulatory antibodies for the treatment of cancer and autoimmune diseases. […] May 3, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2017 French Biotech gets a Second Opportunity to Fight Liver Fibrosis Genkyotex, a French biotech with an eye on NASH, has received FDA approval to initiate a Phase II trial in primary biliary cholangitis. Genkyotex’s lead candidate, GKT831, failed to prove its efficacy in a Phase II trial for diabetic nephropathy a couple of years ago. Now, the company is taking a second shot by targeting liver […] May 3, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2017 Unexpected Side Effects: Are we Ready for the Rise of Immunotherapies? As immunotherapies are moving from large academic centers to clinics across the world, doctors are realizing that releasing the breaks of the immune system comes with serious risks – and that research on its adverse effects is lagging behind. This week, AstraZeneca’s anti-PD-L1 antibody durvalumab received FDA approval to treat patients with metastatic urothelial carcinoma, making […] May 3, 2017 - 4 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 2 May 2017 Novartis Gains Access to Celyad’s allogenic CAR-T cell patents Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR-T cells in a non-exclusive license agreement, worth up to €88M. Celyad is developing “off-the-shelf” therapies, based on engineering donor-derived allogeneic T cells. Despite a recent public dispute with its key rival Cellectis regarding the validity of Celyad’s US patents, Novartis has now entered a non-exclusive […] May 2, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 2 May 2017 French HIV Cure Reduces Viral Reservoirs for the First Time Ever Abivax has announced results from a Phase IIa trial that reveal the first proof in human of viral load reduction of hidden HIV reservoirs. Abivax is developing a functional HIV cure that, unlike current antiretroviral therapy (ART), could completely eliminate the virus and prevent it from coming back when the treatment is stopped. Results from a Phase IIa […] May 2, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 May 2017 Entrepreneurs, Academics & Entrepreneurial Academics succeed in Berlin With Berlin’s plethora of life science research and academia, opportunities abound for biotech entrepreneurs. Here’s how the city bridges the gap between science and business! So much research, so many opportunities for academics and entrepreneurs. Berlin boasts 35 large research institutions focused on life sciences, and around 130 hospitals — including Europe’s largest and most […] May 2, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 29 Apr 2017 These Bioartists Turn Cell-to-Cell Communication in your Body into Sound Thought Collider and David Young have developed an installation that transforms the faint communication signals between your skin cells into sounds. Artist duo Thought Collider is comprised of Mike Thompson, from the UK, and Susana Cámara Leret, from Spain. Based in Amsterdam and London, they experiment with the living nature of our bodies and microorganisms. Their […] April 29, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Apr 2017 The Tires of the Future will be made with… Dandelions? Continental, famous producer of tires, is creating a research facility in Germany to investigate the use of rubber extracted from dandelions. An eventual switch to the material would mean less environmental impact, and maybe even better tires. The “green pet project” of Continental, a giant automotive manufacturer with almost €40Bn yearly revenues, consists of replacing conventional natural […] April 28, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email